Aristotle Capital Management LLC Reduces Position in Merck & Co., Inc. $MRK

Aristotle Capital Management LLC trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK) by 3.9% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 7,817,938 shares of the company’s stock after selling 317,614 shares during the quarter. Aristotle Capital Management LLC’s holdings in Merck & Co., Inc. were worth $656,167,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Chemung Canal Trust Co. boosted its holdings in Merck & Co., Inc. by 21.1% during the 3rd quarter. Chemung Canal Trust Co. now owns 76,338 shares of the company’s stock valued at $6,407,000 after acquiring an additional 13,285 shares during the period. First Pacific Financial grew its position in Merck & Co., Inc. by 14.7% in the 3rd quarter. First Pacific Financial now owns 47,555 shares of the company’s stock valued at $3,991,000 after acquiring an additional 6,082 shares during the last quarter. Diversified Trust Co increased its stake in Merck & Co., Inc. by 9.6% in the third quarter. Diversified Trust Co now owns 207,838 shares of the company’s stock worth $17,444,000 after purchasing an additional 18,187 shares during the period. Caxton Associates LLP increased its stake in Merck & Co., Inc. by 23.3% in the second quarter. Caxton Associates LLP now owns 39,421 shares of the company’s stock worth $3,121,000 after purchasing an additional 7,458 shares during the period. Finally, NEOS Investment Management LLC lifted its position in shares of Merck & Co., Inc. by 39.9% during the third quarter. NEOS Investment Management LLC now owns 347,684 shares of the company’s stock worth $29,181,000 after purchasing an additional 99,074 shares during the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Unusually large call buying: traders bought ~672,962 call options on Friday (a ~1,339% jump vs. typical daily call volume), signaling heavy bullish speculation or hedging interest that can lift near-term implied volatility and upside pressure on MRK shares.
• Positive Sentiment: Phase 3 WELIREG data and regulatory filings deepen Merck’s oncology growth story — new Phase 3 results for belzutifan (WELIREG) combos with KEYTRUDA or LENVIMA show meaningful improvement in RCC; FDA filings with priority reviews/PDUFA dates for 2026 could expand label and revenue runway. Merck’s WELIREG Kidney Cancer Trials Deepen Oncology Growth Story
• Positive Sentiment: Analyst upgrades/price-target raises: Wells Fargo raised its price target to $150 and assigned an overweight rating, and Leerink lifted its target as well — both moves increase institutional demand signals and implied upside for MRK. Benzinga Leerink Raises Merck & Co. Inc. (MRK) Price Target
• Positive Sentiment: RBC Capital maintains a Buy rating, reinforcing analyst support and potentially bolstering demand from long-only managers. RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)
• Positive Sentiment: Bullish price commentary: coverage and price-target pieces (e.g., 247WallStreet) argue broader upside (some scenarios to $150) based on drug pipeline potential, supporting a favorable narrative among momentum investors. Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150
• Neutral Sentiment: Market report on Ovidrel/Ovitrelle highlights expanding fertility market opportunities that could be a modest long-term tailwind for related Merck products, but it’s not an immediate revenue catalyst. Ovidrel or Ovitrelle Market Research Report 2026
• Neutral Sentiment: Misc. coverage items (e.g., stock-picking lists and unrelated biotech moves) mention MRK in broader contexts but are unlikely to materially move the stock on their own. 1 Unpopular Stock That Deserves Some Love and 2 We Avoid ImmunityBio Stock Soars 295% YTD

Merck & Co., Inc. Price Performance

MRK opened at $115.61 on Friday. The company has a market capitalization of $285.84 billion, a price-to-earnings ratio of 15.88, a PEG ratio of 2.24 and a beta of 0.27. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14. The business’s fifty day simple moving average is $115.26 and its 200-day simple moving average is $99.68.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.03. The firm had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, equities research analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 46.70%.

Analyst Upgrades and Downgrades

MRK has been the subject of a number of recent analyst reports. Cantor Fitzgerald boosted their target price on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Merck & Co., Inc. in a research note on Monday, December 29th. Wall Street Zen lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. BMO Capital Markets raised shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $82.00 to $130.00 in a research report on Thursday, December 18th. Finally, Zacks Research downgraded shares of Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a research note on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $126.81.

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP Richard R. Deluca sold 37,685 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the transaction, the executive vice president directly owned 160,174 shares in the company, valued at approximately $19,368,240.08. This trade represents a 19.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Robert M. Davis sold 47,434 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $118.04, for a total transaction of $5,599,109.36. Following the transaction, the chief executive officer directly owned 443,602 shares in the company, valued at approximately $52,362,780.08. The trade was a 9.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 320,176 shares of company stock worth $38,281,735. 0.13% of the stock is currently owned by company insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.